Skip to content

13F-HR filed by BVF INC/IL

BVF INC/IL filed this 13F-HR for the quarter ended 2014-06-30, filed 2014-08-14, with 29 holding rows worth $632,347,000.

Accession
0000921895-14-001872
Filed
2014-08-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q2 2014

A holdings report, 29 entries on the cover page, a total value of $632,347,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $632,347,000 with VALUE read as thousands by filing date, 13F file number 028-06800. The quarter's positions are built on this report. The resolved quarter.

Other managers

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
IRONWOOD PHARMACEUTICALS INC46333X108COMMON STOCK9,208,909$141,173,000thousands by filing date
LIGAND PHARMACEUTICALS INC53220K504COM NEW1,893,123$117,923,000thousands by filing date
ARRAY BIOPHARMA INC COM04269X105Stock14,715,786$67,104,000thousands by filing date
CHEMOCENTRYX INC16383L106COM8,181,816$47,864,000thousands by filing date
RECEPTOS, INC.756207106COMMON STOCK910,600$38,792,000thousands by filing date
ONCOTHYREON INC682324108COM9,858,278$31,941,000thousands by filing date
TARGACEPT INC87611R306COM6,655,128$30,015,000thousands by filing date
EXELIXIS INC30161QAC8NOTE 4.250% 8/129,725,000$25,266,000thousands by filing dateprincipal
FIVE PRIME THERAPEUTICS INC.33830X104Common Stock1,253,000$19,484,000thousands by filing date
ONCOMED PHARMACEUTICALS INC COM68234X102Stock825,647$19,238,000thousands by filing date
ARRAY BIOPHARMA INC04269XAA3NOTE 3.000% 6/018,500,000$18,523,000thousands by filing dateprincipal
REGADO BIOSCIENCE INC75874Q107COM2,607,091$17,702,000thousands by filing date
QLT INC746927102COMMON STOCK2,370,263$14,648,000thousands by filing date
TREVENA INC89532E109COM1,118,743$6,321,000thousands by filing date
CYTOKINETICS INC23282W605COM NEW1,317,000$6,295,000thousands by filing date
ARQULE INC04269E107COM3,124,887$4,844,000thousands by filing date
EXELIXIS INC COM30161Q104Stock1,000,000$3,390,000thousands by filing date
ONCOGENEX PHARMACEUTICALS IN68230A106COM862,069$3,216,000thousands by filing date
BIOLINERX LTD-SPONS ADR09071M106SPON1,501,000$3,122,000thousands by filing date
KALOBIOS PHARMACEUTICALS INC48344T100COM1,162,000$2,649,000thousands by filing date
ANTHERA PHARMACEUTCLS INC03674U201Common equity shares559,624$1,897,000thousands by filing date
ACHAOGEN INC004449104COM125,000$1,745,000thousands by filing date
UNIQURE NVN90064101SHS125,000$1,699,000thousands by filing date
PALATIN TECHNOLOGIES INC696077403COM PAR $ .011,610,652$1,595,000thousands by filing date
BIND THERAPEUTICS INC05548N107Cmn116,000$1,529,000thousands by filing date
REGULUS THERAPEUTICS INC75915K101COM184,999$1,487,000thousands by filing date
SOPHIRIS BIO INC F83578Q209FOREIGN CANADIAN600,000$1,344,000thousands by filing date
BIOTA PHARMACEUTIALS INC090694100COM435,900$1,242,000thousands by filing date
TRANSCEPT PHARMACEUTICALS IN89354M106COM150,000$299,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0000921895-14-001872this filing2014-08-14acceptance time not in the bulk data set